Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia

J. Demeter, Gerald Messer, Hubert Schrezenmeier

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Immune-mediated inhibition of hematopoiesis has been suspected as a major cause of the suppressed growth of progenitor cells in aplastic anemia (AA). Overproduction of TNF-α by bone marrow and peripheral blood-derived cells was shown to be of pathogenetic importance. Genetic factors have been suggested by higher specific histocompatibility antigen frequencies among AA patients as a group and among those unresponsive to immunosuppressive therapy with cyclosporine. In the present work we expand on the evidence for the contribution of the TNF system to therapeutic responses in patients with AA. The response to immunosuppressive therapy at 3 months was found to be significantly more frequent among carriers of the TNF2 (TNF -308 A) gene (TNF2 homozygotes and heterozygotes of the TNF-α promoter/enhancer polymorphism) than among those patients not carrying the TNF2 gene. The allelic distribution of the LT-α (TNF-β) NcoI and IL-1 receptor antagonist variable number tandem repeat (VNTR) polymorphisms did not differ among the subgroups of patients. The association of the TNF-α genotype with a response to immunosuppressive therapy points to an immunogenetic association that may contribute to the pathogenesis and therapeutic response of aplastic anemia.

Original languageEnglish
Pages (from-to)566-569
Number of pages4
JournalAnnals of Hematology
Volume81
Issue number10
DOIs
Publication statusPublished - 2002

Fingerprint

Aplastic Anemia
Tumor Necrosis Factor-alpha
Immunosuppressive Agents
Therapeutics
Immunogenetics
Minisatellite Repeats
Histocompatibility Antigens
Interleukin-1 Receptors
Hematopoiesis
Homozygote
Heterozygote
Cyclosporine
Genes
Blood Cells
Stem Cells
Bone Marrow
Genotype
Growth

Keywords

  • Aplastic anemia
  • Immunosuppressive treatment
  • Polymorphism
  • TNF-α

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. / Demeter, J.; Messer, Gerald; Schrezenmeier, Hubert.

In: Annals of Hematology, Vol. 81, No. 10, 2002, p. 566-569.

Research output: Contribution to journalArticle

Demeter, J. ; Messer, Gerald ; Schrezenmeier, Hubert. / Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. In: Annals of Hematology. 2002 ; Vol. 81, No. 10. pp. 566-569.
@article{769036d07f05468d97ffc52f29a36d22,
title = "Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia",
abstract = "Immune-mediated inhibition of hematopoiesis has been suspected as a major cause of the suppressed growth of progenitor cells in aplastic anemia (AA). Overproduction of TNF-α by bone marrow and peripheral blood-derived cells was shown to be of pathogenetic importance. Genetic factors have been suggested by higher specific histocompatibility antigen frequencies among AA patients as a group and among those unresponsive to immunosuppressive therapy with cyclosporine. In the present work we expand on the evidence for the contribution of the TNF system to therapeutic responses in patients with AA. The response to immunosuppressive therapy at 3 months was found to be significantly more frequent among carriers of the TNF2 (TNF -308 A) gene (TNF2 homozygotes and heterozygotes of the TNF-α promoter/enhancer polymorphism) than among those patients not carrying the TNF2 gene. The allelic distribution of the LT-α (TNF-β) NcoI and IL-1 receptor antagonist variable number tandem repeat (VNTR) polymorphisms did not differ among the subgroups of patients. The association of the TNF-α genotype with a response to immunosuppressive therapy points to an immunogenetic association that may contribute to the pathogenesis and therapeutic response of aplastic anemia.",
keywords = "Aplastic anemia, Immunosuppressive treatment, Polymorphism, TNF-α",
author = "J. Demeter and Gerald Messer and Hubert Schrezenmeier",
year = "2002",
doi = "10.1007/s00277-002-0544-6",
language = "English",
volume = "81",
pages = "566--569",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia

AU - Demeter, J.

AU - Messer, Gerald

AU - Schrezenmeier, Hubert

PY - 2002

Y1 - 2002

N2 - Immune-mediated inhibition of hematopoiesis has been suspected as a major cause of the suppressed growth of progenitor cells in aplastic anemia (AA). Overproduction of TNF-α by bone marrow and peripheral blood-derived cells was shown to be of pathogenetic importance. Genetic factors have been suggested by higher specific histocompatibility antigen frequencies among AA patients as a group and among those unresponsive to immunosuppressive therapy with cyclosporine. In the present work we expand on the evidence for the contribution of the TNF system to therapeutic responses in patients with AA. The response to immunosuppressive therapy at 3 months was found to be significantly more frequent among carriers of the TNF2 (TNF -308 A) gene (TNF2 homozygotes and heterozygotes of the TNF-α promoter/enhancer polymorphism) than among those patients not carrying the TNF2 gene. The allelic distribution of the LT-α (TNF-β) NcoI and IL-1 receptor antagonist variable number tandem repeat (VNTR) polymorphisms did not differ among the subgroups of patients. The association of the TNF-α genotype with a response to immunosuppressive therapy points to an immunogenetic association that may contribute to the pathogenesis and therapeutic response of aplastic anemia.

AB - Immune-mediated inhibition of hematopoiesis has been suspected as a major cause of the suppressed growth of progenitor cells in aplastic anemia (AA). Overproduction of TNF-α by bone marrow and peripheral blood-derived cells was shown to be of pathogenetic importance. Genetic factors have been suggested by higher specific histocompatibility antigen frequencies among AA patients as a group and among those unresponsive to immunosuppressive therapy with cyclosporine. In the present work we expand on the evidence for the contribution of the TNF system to therapeutic responses in patients with AA. The response to immunosuppressive therapy at 3 months was found to be significantly more frequent among carriers of the TNF2 (TNF -308 A) gene (TNF2 homozygotes and heterozygotes of the TNF-α promoter/enhancer polymorphism) than among those patients not carrying the TNF2 gene. The allelic distribution of the LT-α (TNF-β) NcoI and IL-1 receptor antagonist variable number tandem repeat (VNTR) polymorphisms did not differ among the subgroups of patients. The association of the TNF-α genotype with a response to immunosuppressive therapy points to an immunogenetic association that may contribute to the pathogenesis and therapeutic response of aplastic anemia.

KW - Aplastic anemia

KW - Immunosuppressive treatment

KW - Polymorphism

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=0036956560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036956560&partnerID=8YFLogxK

U2 - 10.1007/s00277-002-0544-6

DO - 10.1007/s00277-002-0544-6

M3 - Article

C2 - 12424537

AN - SCOPUS:0036956560

VL - 81

SP - 566

EP - 569

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 10

ER -